Table 1

Demographic and clinical characteristics of the enrolled population by first-line treatment

ICIs
n=446
MAPKi
n=222
Overall
n=668
BMI continuous
 Mean (SD)27.1 (5.0)27.0 (4.7)27.1 (4.9)
 Median (Q1 to Q3)26.3 (23.7 to 29.7)26.3 (23.7 to 29.7)26.3 (23.7 to 29.7)
 Min to max14.8 to 50.417.8 to 41.014.8 to 50.4
BMI class, n (%)
 Normal (BMI <25)166 (37.2)83 (37.4)249 (37.3)
 Overweight (BMI (25 to 30))176 (39.5)85 (38.3)261 (39.1)
 Obese (BMI≥30)104 (23.3)54 (24.3)158 (23.7)
Gender, n (%)
 Female174 (39.0)99 (44.6)273 (40.9)
 Male272 (61.0)123 (55.4)395 (59.1)
Age
 Mean (SD)63.5 (13.4)56.9 (13.1)61.3 (13.6)
 Median (Q1 to Q3)65.5 (54.3 to 73.7)57.5 (47.7 to 66.7)62.1 (52.2 to 71.5)
 Min to max22.9 to 93.123.0 to 91.122.9 to 93.1
BRAF mutation, n (%)
 Negative373 (84.4)0 (0.0)373 (56.2)
 Positive69 (15.6)222 (100)291 (43.8)
 Missing404
Disease stage, n (%)
 M1a+M1b205 (46.4)80 (36.0)285 (42.9)
 M1c+M1d237 (53.6)142 (64.0)379 (57.1)
 Missing404
LDH values, n (%)
 0304 (70.9)112 (50.9)416 (64.1)
 ≥1125 (29.1)108 (49.1)233 (35.9)
 Missing17219
ECOG PS values, n (%)
 0262 (59.0)98 (44.1)360 (54.1)
 ≥1182 (41.0)124 (55.9)306 (45.9)
 Missing202
  • BMI, body mass index; ECOG, Eastern Cooperative Oncology Group Performance Status; ICIs, immune checkpoint inhibitors; LDH, lactate dehydrogenase; MAPKi, mitogen activated pathway kinase inhibitors; Max, maximum; Min, minimum; n, number of subjects; Q, quartile.